Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

New EUA Allows More Home Collection Of Saliva Samples For COVID-19 Testing

Executive Summary

The US Food and Drug Administration has granted Emergency Use Authorization (EUA) to Spectrum Solutions’ saliva collection system, which allows individuals to take samples of their own saliva to test for the virus.

You may also be interested in...



FDA Authorizes First At-Home COVID-19 Saliva Sample Collection Kit

The US agency has authorized the first COVID-19 test to use at-home saliva sample collection. Rutgers Clinical Genomics Laboratory landed the emergency use authorization.

Medicare Proposes NTAP For Breakthrough Treatment Of Spinal Condition

US Medicare has granted a new technology add-on payment (NTAP) for an innovative technology designed to treat adult spinal deformity.

First EUA In US For OTC Test To Detect COVID-19, Flu, RSV Granted To Labcorp

Agency issued an emergency use authorization to Labcorp for its OTC that detects COVID-19, flu and respiratory syncytial virus.

Topics

UsernamePublicRestriction

Register

MT144355

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel